Biotech IPO Stock Plan Evergreens

posted in: Uncategorized | 0

Although not really news, we did pull the stock plan evergreens for most of the recent  “standard” IPOs.  By standard, we mean domestic companies listing on US exchanges that have really not been subject to public reporting rules previously.  Virtually … Continued

Severance for Small Cap Biotechs

posted in: Plan Design, Uncategorized | 0

We recently performed severance analyses for about 40 public companies with market caps below $1 billion. The group was mostly comprised of drug development companies without substantial revenues but there were a few device and service health care companies–also without … Continued

Reforming ISS and Glass Lewis

posted in: Uncategorized | 0

A nice and sensible wish list from old friend Jim Barrall at Latham.  http://www.agendaweek.com/c/625494/70744/five_ways_reform_glass_lewis?referrer_module=issueHeadline&module_order=2

IRC 409A and Equity

posted in: Uncategorized | 0

The following is excerpted from our book “409A Administration Handbook” (which is about to come out with a new name and an extensive new valuation section). Q. 25. Are stock options subject to § 409A? Generally not, though there is … Continued

1 2 3